IPHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as IPHYF
Innate Pharma SA
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 1, 2026
$1.46+0.03 (+2.10%)
Close on Oct 19, 2026
Innate Pharma statistics
Financials through Jun 30, 2026, price-based ratios appear once a share price is available, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Innate Pharma | Industry median |
|---|---|---|
| Market Cap | €122.25M | €878.09M |
| Enterprise Value | €115.79M | €706.41M |
| PS Ratio | 13.58 | 6.85 |
Enterprise value
| Measure | Innate Pharma | Industry median |
|---|---|---|
| EV / Sales | 12.86 | 3.86 |
Income (trailing twelve months)
| Measure | Innate Pharma | Industry median |
|---|---|---|
| Revenue | €9.01M | €465.66M |
| Operating Income | -€54.01M | -€54.01M |
| Pretax Income | -€49.18M | -€47.40M |
| EBITDA | -€52.62M | -€42.85M |
| EPS (Diluted) | -0.55 EUR | -0.55 EUR |
Margins
| Measure | Innate Pharma | Industry median |
|---|---|---|
| Operating Margin | -599.8% | -33.2% |
| Pretax Margin | -546.1% | -36.6% |
| EBITDA Margin | -584.4% | -28.6% |
| FCF Margin | -587.4% | -24.4% |
Returns
| Measure | Innate Pharma | Industry median |
|---|---|---|
| Return on Capital Employed (ROCE) | -2888.1% | -23.8% |
Growth
| Measure | Innate Pharma | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -55.2% | -1.08% |
| Revenue Growth (3Y CAGR) | -46.2% | 1.61% |
| Revenue Growth (5Y CAGR) | -33.6% | 14.0% |
Balance sheet
| Measure | Innate Pharma | Industry median |
|---|---|---|
| Cash & Short-Term Investments | €6.46M | €199.29M |
| Total Debt | €2.10K | €184.06M |
| Net Cash (Debt) | €6.46M | €111.50M |
| Net Cash Per Share | 0.07 EUR | 1.53 EUR |
| Working Capital | -€13.26M | €119.55M |
Financial position
| Measure | Innate Pharma | Industry median |
|---|---|---|
| Current Ratio | 0.60 | 3.49 |
| Quick Ratio | 0.46 | 1.51 |
| Interest Coverage | -17.31 | -0.71 |
Cash flow (trailing twelve months)
| Measure | Innate Pharma | Industry median |
|---|---|---|
| Operating Cash Flow | -€52.76M | -€42.16M |
| Capital Expenditures | -€140.00K | -€2.34M |
| Free Cash Flow | -€52.90M | -€52.90M |
| FCF Per Share | -0.56 EUR | -0.48 EUR |
Efficiency
| Measure | Innate Pharma | Industry median |
|---|---|---|
| Asset Turnover | 0.14 | 0.31 |
| Revenue Per Employee | €49.75K | €855.98K |
| Employee Count | 181 | 304 |
Dividends and yields
| Measure | Innate Pharma | Industry median |
|---|---|---|
| FCF Yield | -43.3% | -13.6% |
| Buyback Yield | -12.3% | -11.4% |
| Shareholder Yield | -12.3% | -11.4% |
Shares
| Measure | Innate Pharma | Industry median |
|---|---|---|
| Shares Outstanding | 93,719,300 | 99,540,150 |
| Shares Change (YoY) | 10.5% | 5.61% |
| Float | 78,574,400 | 78,574,400 |
| Shares Held by Insiders | 16.2% | 9.05% |
| Shares Held by Institutions | 0.21% | 13.8% |
Taxes
| Measure | Innate Pharma | Industry median |
|---|---|---|
| Income Tax | €0 | €80.00K |
Scores
| Measure | Innate Pharma | Industry median |
|---|---|---|
| Altman Z-Score | -4.36 | 1.13 |
Calculated by StockData from Innate Pharma's SEC filings. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.